Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability
of tumor cells to grow and spread. Others find tumor cells and help kill them or carry
tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer
by blocking blood flow to the tumor. Giving combination chemotherapy together with
bevacizumab and cetuximab may kill more tumor cells. This phase II trial is studying how well
giving combination chemotherapy together with bevacizumab and cetuximab works in treating
patients with stage IV colorectal cancer that cannot be removed by surgery.